Sarepta Therapeutics Inc

SRPT remains in a clear Stage 4 decline with a sequence of lower highs and lower lows, and EMAs are rejecting rally attempts. Medium-term bias is bearish, and short-term conditions favor additional downside as price fails at the 9/20 EMA band and 50 DMA. Execution is Sell Now on rallies into EMA/50 DMA resistance to participate in continuing downtrend momentum.

• ↑Q1 net product revenue hit $331M, targeting $1.2–1.4B in 2026 guidance.
• ↑$748M cash position funds R&D and siRNA pipeline without dilution.
• ↓Negative profitability metrics and earnings yield highlight efficiency challenges.